Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:
Women's Hub News
 

Back to home » News & Views » Treatment News


 

December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007

emailrssprint

May 27, 2008

Gold Nanoparticles Revive HIV Drug’s Prospects

Adding minuscule bits of gold, called nanoparticles, to a failed HIV drug causes it to work much better without creating dangerous side effects, say the authors of a study published online on May 13 in the Journal of the American Chemical Society and reported by ScienceDaily.

Takeda Pharmaceuticals’ TAK-779 is an entry inhibitor that was designed to bind to the CCR5 receptor on the surface of CD4 cells. HIV uses this receptor to enter and infect CD4 cells. For TAK-779 to work properly, it requires an aluminum salt molecule. This molecule, however, was found to cause side effects. Because the drug doesn’t work without the molecule, its development was halted indefinitely.

Christian Melander, PhD, from the University of North Carolina, Chapel Hill, and his colleagues questioned whether adding gold nanoparticles in place of the salt molecule might allow TAK-779 to work without adding side effects. When Melander’s team joined a fragment of the drug to a gold nanoparticle, they found that the combo was able to shut down HIV reproduction in test-tube studies.

Because the human body does not react negatively to gold, Melander’s team believes that the new version of TAK-779 bound to gold nanoparticles shouldn’t have significant side effects. “We've discovered a non-harmful way to improve the strength and efficacy of an important drug,” Melander says. “There’s no reason to think that this same process can’t be used with similar effect on other existing drugs.”

In fact, researchers from Tibotec and other companies are actively exploring ways to use nanoparticles to create versions of both approved and experimental HIV drugs that may only need to be taken once a month or even less often.

NEW! Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]


Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Blogs by HIV+ Women
Regan Ann Michelle Annette

Read the blogs
Woman of the Month
Beth Benne: Nursing HIV Awareness
Beth Benne, RN, is HIV negative, but the virus has impacted her life. She currently supervises a biannual HIV/AIDS awareness week as the director of the student health center at Pierce College, a community commuter school in Woodland Hills, California. 


Woman of the Month is supported by exclusive advertising from Gilead.
Overheard in the Women's Forum
"I recently met a guy who is negative. I did tell him about my status and he decided to kiss me anyway (we didn't go further than that). But a day later, he called and said that he actually had a mouth ulcer that time when we kissed and he was very worried. Asked if he can get the virus from me that way. For that moment, I felt so insulted and yet I felt so bad. It was my first time having a contact with a "negative" guy."

from Positive Women


Join the forums

Smart + Strong Network
POZ Magazine
POZ Personals
POZ Mentor
POZ ASO Directory
AIDSmeds
Real Health Magazine
TuSalud Magazine
ComboCards
Rx Info Cards
Also visit POZ on...
Facebook

MySpace

YouTube

 
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy